Search research articles
Contact Us
Filters
Showing results (291-300 of 336) with videos related to
Page
of 34
Sort By:
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
Investigational New Drugs
|
January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 21, 2018
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma
Jean-François Fournier, Yushma Bhurruth-Alcor, Branislav Musicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
American Journal of Obstetrics and Gynecology
|
October 6, 2024
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia
Adrien Msika, Virginie Mathias, Marina Boudigou, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 19, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Page
of 34
Search research articles
Search
Showing results (291-300 of 336) with videos related to
Sort By:
Page
of 34
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
Investigational New Drugs
|
January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 21, 2018
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma
Jean-François Fournier, Yushma Bhurruth-Alcor, Branislav Musicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
American Journal of Obstetrics and Gynecology
|
October 6, 2024
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia
Adrien Msika, Virginie Mathias, Marina Boudigou, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 19, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Page
of 34